Lineage Cell Therapeutics, Inc. (LCTX) Social Stream
LINEAGE CELL THERAPEUTICS INC (LCTX) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering LCTX.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-12-02 | 5 | $8 | $5 | $6.4 | $1.22 | 424.59% |
| 2021-12-22 | 6 | $8 | $5 | $6.4 | $1.22 | 424.59% |
| 2022-06-03 | 5 | $8 | $6 | $6.75 | $1.22 | 453.28% |
| 2022-06-14 | 6 | $8 | $4 | $6.2 | $1.22 | 408.2% |
| 2022-08-16 | 7 | $8 | $4 | $6 | $1.22 | 391.8% |
| 2022-10-04 | 7 | $9 | $4 | $6.166 | $1.22 | 405.41% |
| 2023-05-12 | 8 | $9 | $4 | $6 | $1.22 | 391.8% |
| 2023-08-11 | 7 | $9 | $4 | $6 | $1.22 | 391.8% |
| 2023-10-19 | 6 | $7 | $4 | $5.5 | $1.22 | 350.82% |
| 2023-11-10 | 6 | $7 | $4 | $5.5 | $1.22 | 350.82% |
| 2023-11-20 | 6 | $7 | $2 | $4.833 | $1.22 | 296.15% |
The Trend in the Analyst Price Target
LCTX's average price target has moved down $1.17 over the prior 27 weeks.
Over the past 38 weeks, LCTX's average upside potential has been 347.77%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-13 | 8 | 9 | 4 | 6.0 | 1.42 | 322.54% |
| 2023-04-26 | 8 | 9 | 4 | 6.0 | 1.35 | 344.44% |
| 2023-05-12 | 8 | 9 | 4 | 6.0 | 1.38 | 334.78% |
| 2023-10-20 | 7 | 7 | 4 | 5.5 | 1.20 | 358.33% |
| 2023-11-10 | 6 | 7 | 4 | 5.5 | 1.04 | 428.85% |
LCTX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 52 weeks, LCTX's average broker recommendation rating improved by 0.25.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for LCTX as an investment opportunity.
- LINEAGE CELL THERAPEUTICS INC's average analyst price target is higher than 58.94% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, LINEAGE CELL THERAPEUTICS INC's upside potential (average analyst target price relative to current price) is higher than 1019.71% of them.
- LCTX has a greater number of analysts covering the stock than 810.81% of stocks in the small market cap category.
- In the context of stocks in the small market cap category, LINEAGE CELL THERAPEUTICS INC's variance in analysts' estimates is lower than -631.53% of them.
In the Pharmaceutical Products industry, CVM, CRBU, and FUSN are the three stocks most similar to LINEAGE CELL THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is LCTX a Buy, Hold or Sell? See the POWR Ratings now!